On December 17, 2020, the Board of Directors of Kiniksa Pharmaceuticals, Ltd. appointed Mark Ragosa as the Company’s VP, assuming the role of principal financial officer from Michael Megna, who will continue to serve in his role as the Company’s VP, Finance and Chief Accounting Officer and principal accounting officer. Mr. Ragosa, 46, has served as the Company’s VP, Investor Relations and Finance since May 2020 and prior to that served as the Company’s VP, Investor Relations since May 2018. On December 16, 2020, Qasim Rizvi, the Company’s SVP of Operations and Chief Commercial Officer, informed the Company that he plans to resign from his position after a transition period ending in January 2021 to assume the position of Chief Executive Officer of a biotechnology company based in Cambridge, Massachusetts. Ross Moat, the Company’s VP and General Manager of the Rilonacept Franchise, who has been leading the rilonacept launch readiness activities, will continue to focus on commercialization plans for rilonacept in recurrent pericarditis, for which the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s supplemental Biologics License Application (“sBLA”) for recurrent pericarditis and granted priority review with an assigned Prescription Drug User Fee Act (“PDUFA”) goal date of March 21, 2021. Mr. Moat joined the Company in June 2019 and will be responsible for leading the Company’s operations for rilonacept, if approved. Prior to joining Kiniksa, Mr. Moat served as VP, EMEA Marketing and Commercial Operations from May 2018 to June 2019 at AveXis Inc., a Novartis AG company, where he led launch readiness planning and execution.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).